WT1 126-134 mutant (HLA-A*02:01) 126Y YMFPNAPYL
€210.00*
Description
Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance. The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy. This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. YMFPNAPYL is a linear peptidic epitope (epitope ID 158523), tested in MHC ligand assays.
TechData
| Sequence: | YMFPNAPYL |
| Gene: | WT1 |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Wilms-Tumor-Protein |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |